Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(165 products)
- Bcr-Abl(117 products)
- EGFR(562 products)
- FAK(72 products)
- FLT(89 products)
- Fibroblast Growth Factor Receptor (FGFR)(177 products)
- JAK(245 products)
- PDGFR(127 products)
- RAAS(86 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(52 products)
- VDA(2 products)
- VEGFR(239 products)
Show 6 more subcategories
Found 2243 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BCR-ABL-IN-6
CAS:BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49VS 8
CAS:VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.Formula:C26H20F3N3O3Color and Shape:SolidMolecular weight:479.45EGFR/HER2-IN-2
CAS:EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11EGFR-IN-25
CAS:EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76EGFR-IN-54
CAS:EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51NSC114792
CAS:NSC114792 is a selective JAK3 inhibitor.Formula:C26H32N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.62SUN13837
CAS:SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.Formula:C21H29N5O2Color and Shape:SolidMolecular weight:383.49TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42EGFR/HER2-IN-3
CAS:EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49FLT3-IN-18
CAS:FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purity:99.05%Color and Shape:SolidMolecular weight:297.35Ref: TM-T72653
1mg145.00€5mg250.00€10mg340.00€25mg573.00€50mg879.00€100mg1,314.00€1mL*10mM (DMSO)462.00€EGFR-IN-69
CAS:EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64VEGFR2 Kinase Inhibitor II
CAS:VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.Formula:C17H15BrN2OColor and Shape:SolidMolecular weight:343.22BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53EGFR-IN-31
CAS:EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67FLT3/D835Y-IN-1
CAS:FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43EGFR-IN-60
CAS:EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.Formula:C28H28Cl2N6OColor and Shape:SolidMolecular weight:535.47ZT55
CAS:ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.Formula:C17H16N2O3Color and Shape:SolidMolecular weight:296.32VEGFR-2-IN-24
CAS:VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.Formula:C28H23N3O6SColor and Shape:SolidMolecular weight:529.56
